PMOS: The New Name for PCOS Explains Its Complex Hormonal & Metabolic Impact

Global health experts have officially rebranded polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS), marking a decade-long effort to better reflect the condition’s complex, multisystem impacts on women’s health. The name change, announced on May 12, 2026, and published in The Lancet, aims to correct persistent misconceptions—particularly the misleading focus on ovarian cysts—that have delayed diagnoses and inadequate care for millions worldwide.

The new name, PMOS, emphasizes the hormonal and metabolic disruptions central to the condition, which affects approximately 1 in 8 women globally, or over 170 million individuals, according to the Endocrine Society. The term polyendocrine highlights the broader endocrine dysfunction, while metabolic underscores the condition’s links to insulin resistance, cardiometabolic risks, and long-term health complications. The shift away from “polycystic” is deliberate: experts clarify that the ovaries of women with PMOS do not contain abnormal cysts but rather numerous small, immature follicles—a normal ovarian feature that becomes more prevalent in PMOS.

“The previous name reduced a complex, multisystem disorder to a misunderstanding about cysts and ovaries,” said Professor Helena Teede, director of Monash University’s Monash Centre for Health Research & Implementation and lead of the name-change initiative. “This contributed to delayed diagnoses and inadequate care for those affected.” The renaming follows a global consensus involving over 50 patient and professional organizations, including the Endocrine Society, and was endorsed at the European Congress of Endocrinology in Prague.

The rebranding is part of a broader push to improve recognition and management of PMOS, which extends beyond reproductive health to impact metabolic function, mental health, skin conditions, and fertility. “PMOS is not just a gynecologic condition—it’s a chronic, multisystem hormonal disorder,” said Dr. Rekha B. Kumar, an endocrinologist at NewYork-Presbyterian/Weill Cornell Medical Center. “The new name reflects its true scope: reproductive health, cardiometabolic risks, dermatology, and mental well-being.”

### Why the Name Matters: Debunking Common Myths

The renaming addresses long-standing misconceptions that have hindered early detection and appropriate treatment. Below are five key myths clarified by experts:

1. Myth: PMOS is primarily about ovarian cysts. The term “polycystic” misled many to believe the condition was defined by abnormal ovarian growths. In reality, PMOS involves hormonal imbalances—particularly elevated androgens (like testosterone)—and metabolic dysfunction. “The cyst language caused unnecessary worry,” noted Dr. Heather G. Huddleston, director of the PMOS Clinic at UCSF Health. “The ovaries contain small follicles, not true cysts, but the broader hormonal and metabolic effects are what drive the condition’s symptoms.”
2. Myth: Irregular periods alone mean you have PMOS. While irregular cycles are a common symptom, they can stem from other causes, including thyroid disorders, pelvic inflammatory disease, or extreme stress. A diagnosis requires at least two of three criteria from the Rotterdam criteria: irregular ovulation, elevated androgen levels (or symptoms like acne/hirsutism), and polycystic-appearing ovaries on ultrasound (or elevated anti-Müllerian hormone in adults).
3. Myth: PMOS is the same as endometriosis. Though both conditions can cause irregular periods and fertility challenges, their mechanisms differ. Endometriosis involves uterine-like tissue growing outside the uterus, often causing pelvic pain, while PMOS is driven by hormonal and metabolic dysregulation.
4. Myth: Everyone with PMOS has visible symptoms like excess hair or acne. Symptoms vary widely. While high androgens can cause hirsutism (excess hair) or acne, about 1 in 4 women with PMOS do not experience acne, and hair growth patterns differ by ethnicity. “Ethnicity plays a role,” said Dr. Loren Wissner Greene, NYU Langone Health. “Hirsutism is more prevalent in South Asian, Middle Eastern, and Hispanic women but less common in East Asian women.”
5. Myth: PMOS means infertility is inevitable. Though irregular ovulation can impair fertility, treatments—such as medications to induce ovulation—are highly effective. “PMOS-related infertility is treatable,” Huddleston emphasized. “Women should work with providers to address cardiometabolic and mental health comorbidities before attempting conception, as these can impact pregnancy outcomes.”

The name change will be phased in over the next three years, requiring updates to medical guidelines, educational materials, and public awareness campaigns. Experts stress that early diagnosis—through multidisciplinary care involving endocrinologists, gynecologists, and primary care providers—remains critical to managing PMOS effectively.

For women experiencing symptoms such as irregular periods, unexplained weight changes, acne, or hair loss, healthcare providers recommend seeking evaluation using the updated diagnostic criteria. “PMOS can be well managed, especially with early intervention,” said Dr. Anuja Dokras, director of the Penn PCOS Center. “A multidisciplinary approach—addressing metabolic, reproductive, and mental health needs—is key to improving long-term outcomes.”

The renaming of PCOS to PMOS is more than a linguistic update. it signals a paradigm shift in how the medical community and public understand this widespread condition. By acknowledging its multisystem nature, advocates hope to reduce stigma, improve diagnostic accuracy, and ensure women receive the comprehensive care they deserve.